Journal article

A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX

Eugene V McCloskey, Anders Oden, Nicholas C Harvey, William D Leslie, Didier Hans, Helena Johansson, Reinhard Barkmann, Stephanie Boutroy, Jacques Brown, Roland Chapurlat, Petra JM Elders, Yuki Fujita, Claus-C Glueer, David Goltzman, Masayuki Iki, Magnus Karlsson, Andreas Kindmark, Mark Kotowicz, Norio Kurumatani, Timothy Kwok Show all

JOURNAL OF BONE AND MINERAL RESEARCH | WILEY | Published : 2016

Abstract

Trabecular bone score (TBS) is a gray-level textural index of bone microarchitecture derived from lumbar spine dual-energy X-ray absorptiometry (DXA) images. TBS is a bone mineral density (BMD)-independent predictor of fracture risk. The objective of this meta-analysis was to determine whether TBS predicted fracture risk independently of FRAX probability and to examine their combined performance by adjusting the FRAX probability for TBS. We utilized individual-level data from 17,809 men and women in 14 prospective population-based cohorts. Baseline evaluation included TBS and the FRAX risk variables, and outcomes during follow-up (mean 6.7 years) comprised major osteoporotic fractures. The a..

View full abstract

University of Melbourne Researchers

Grants

Awarded by MRC


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Awarded by Novo Nordisk Fonden


Funding Acknowledgements

CG has received consulting fees or honoraria and travel support from MediMaps. DG is a Board member or received consultancy fees from Amgen and Lilly. His institution has received research funding from Amgen, Lilly and Merck. DH is the President of Medimaps. EVM and/or his institution have received consultancy fees, research funding and/or honoraria from the Alliance for Better Bone Health, Amgen, Consilient, GE Lunar, GSK, Hologic, Internis, Lilly, Merck, Novartis, ONO, Pfizer, Roche, Servier, UCB and Wyeth. NH and/or his institution have received consultancy fees, research funding and/or honoraria from the Alliance for Better Bone Health, Amgen, Consilient, Internis, Lilly, Merck, Servier and Shire. AK and/or his institution have received consultancy fees, research funding and/or honoraria for lectures/educational materials from the Amgen, Lilly, MEDA and Shire HGT. TK's institution has received research funding from NIH (US) and RGC (HK). WL and/or his institution have received research funding and/or honoraria Amgen, Genzyme, Lilly and Novartis. JP's institution has received research funding from NHMRC. JT's institution has received research funding from the Japanese Society for the Promotion of Science.